Rox Breathes Easy
This article was originally published in Start Up
Rox Medical, which is developing a device to improve the oxygenation of blood, raised $35 million in a Series C round.
You may also be interested in...
With clear regulatory approval paths in Europe and growing markets in Asia and other developing markets, device executives and investors see international markets as increasingly attractive alternatives for clinical validation, revenue, and regulatory approval.
Essex Woodlands Health Ventures closes on $900 million fund, one of the health care industry's largest.
Nearly a decade into the race to arm pulmonologists with interventional tools to treat emphysema, no clear winner is emerging. Emphasys, which had led the pack in developing a bronchial valve, hit a wall at the FDA. The question is whether competitors can fill the gap.